CompletedNot Applicable

Semaglutide Use in Acute Pulmonary Embolism

United Kingdom18 participantsStarted 2022-01-02

Plain-language summary

Evaluation of circulating endothelial inflammatory biomarkers in response to GLP-1 agonist Semaglutide in acute pulmonary embolism

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Acute pulmonary embolism Exclusion Criteria: Concurrent use of GLP-1 agonist

Endothelial biomarker measurement

Timeframe: 4 weeks

NCT IDNCT06118203

SponsorImperial College London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-04